Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 6/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.56 |
| ▸ | HTR3B | O95264 | 2/20 | 0.56 |
| ▸ | HTR3A | P46098 | 2/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6636311 | 0.89 | NCF1 (1.00) | NCF1ADRB2GAAHTR3EHTR3B | |
| SCHEMBL5133941 | 0.87 | GAA (0.63) | NCF1ADRB2GAANPC1PKM | |
| Hydrochloric Acid SCHEMBL5035840 | 0.86 | GAA (0.62) | NCF1ADRB2GAANPC1PKM | |
| SCHEMBL22441572 | 0.82 | NCF1 (1.00) | NCF1ADRB2HTR3EHTR3BHTR3A | |
| SCHEMBL30061172 | 0.82 | NCF1 (0.70) | NCF1ADRB2PKMALOX15CASP1 | |
| SCHEMBL28754396 | 0.81 | NCF1 (0.55) | NCF1ADRB2GAA | |
| SCHEMBL30061178 | 0.81 | GAA (0.59) | NCF1GAANPC1PKMALOX15 | |
| SCHEMBL24009026 | 0.80 | GAA (0.55) | NCF1ADRB2GAANPC1PKM | |
| SCHEMBL22445574 | 0.80 | GAA (0.55) | NCF1ADRB2GAANPC1PKM | |
| SCHEMBL1043251 | 0.79 | NCF1 (0.70) | NCF1ADRB2PKMALOX15CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12479821-B2 | Quinoline compound and use thereof | MBD Co., Ltd. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | MBD Co., Ltd. (KR) | 2024-08-29 | — | — | US | disclosed |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | MBD CO., LTD (KR) | 2022-12-22 | — | — | US | disclosed |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | MBD CO., LTD (KR) | 2022-12-22 | — | — | US | disclosed |
| WO-2022235091-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | 엠비디 주식회사 | 2022-11-10 | — | — | WO | disclosed |
| WO-2021096335-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | 엠비디 주식회사 | 2021-05-20 | — | — | WO | disclosed |
| WO-2021096335-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | 엠비디 주식회사 | 2021-05-20 | — | — | WO | disclosed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7148221-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7144888-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1717220-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1688408-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | CYP4B1, CYP4A11, CYP3A4 | NCF1 2417/4885ADRB2 916/4885GAA 324/4885 |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | NCF1 2882/4885ADRB2 138/4885GAA 1158/4885 |
| US-12479821-B2 | Quinoline compound and use thereof | CYP4A11, CYP7A1, CYP4B1 | NCF1 2257/4885ADRB2 1647/4885GAA 228/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | NCF1 2221/4885ADRB2 288/4885GAA 940/4885 |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | CYP4A11, CYP4B1, CYP4A22 | NCF1 2403/4885ADRB2 1242/4885GAA 234/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | NCF1 2882/4885ADRB2 138/4885GAA 1158/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | NCF1 2644/4885ADRB2 118/4885GAA 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.